Up-front Testing Is Imperative for Treatment Decisions in RET+ NSCLC
July 29th 2023Deborah B. Doroshow, MD, PhD, discusses the efficacy and toxicity profiles of pralsetinib and selpercatinib and how they influence treatment selection for patients with RET fusion–positive non–small cell lung cancer, and provides insight on several areas of ongoing or potential research in lung cancer.
Lung Cancer Trials Require Modified Eligibility Criteria to Better Reflect Real-World Population
July 28th 2023Edward S. Kim, MD, MBA, discusses necessary changes that would make cancer research more accessible to patients in community settings, multidisciplinary efforts that should take place at every step of the trial design and implementation process, and how future clinical trials should be intentional about the patient demographics.
Tackling Resistance Mechanisms Is the Next Step in Immunotherapy Development for NSCLC
Immunotherapy administered alone or in combination with chemotherapy has become the standard of care across advanced non–small cell lung cancer in several settings, with continued effort devoted to further enhancing and improving upon these treatments.
Perioperative Immunotherapy Improves EFS, But Clouds Optimal Sequencing in Early NSCLC
July 27th 2023Positive event-free survival data from the phase 3 AEGEAN, NEOTORCH, and KEYNOTE-671 trials add further evidence to the benefit of perioperative immunotherapy in early-stage non–small cell lung cancer but have yet to show clear biomarkers of response beyond PD-L1.
Pasi A. Jänne, MD, PhD, details common EGFR mutations in NSCLC, the importance of testing for EGFR mutations in all patients, the clinical implications of overall survival data for adjuvant osimertinib from the ADAURA trial, and ongoing trials examining combination therapies to potentially improve upon the use of single-agent osimertinib.
Glutaminase Inhibition Represents Novel Treatment Strategy in NFE2L2- and KEAP1-Mutated NSCLC
Jonathan Wesley Riess, MD, MS, discusses a phase 1 trial examining the combination of sapanisertib and telaglenastat, and explains why glutaminase inhibition is being investigated as a novel way to treat select patients with non–small cell lung cancer.
EGFR TKI–Based Combos Could Lead to More Tailored First-Line Treatment Options in EGFR-Mutated NSCLC
Leveraging EGFR TKIs as a backbone for combination therapies will be pivotal for expanding treatment options and delivering more personalized therapies in the first-line setting for patients with non–small cell lung cancer harboring EGFR mutations.
Novel Biomarker Testing Could Enhance Immunotherapy Treatment Decisions in NSCLC
PD-L1 and tumor mutational burden are established biomarkers for leveraging immunotherapy in non–small cell lung cancer; however, their use may not be appropriate in determining treatment decisions for all patients.
HER2-Mutated NSCLC Treatment Evolves From Mainstay TKIs to Novel ADCs and Beyond
Antibody-drug conjugates have demonstrated substantial activity in patients with HER2-mutated non–small cell lung cancer, with fam-trastuzumab deruxtecan-nxki showcasing the strongest response rate and progression-free survival benefit to date.